Scientists from Thomas Jefferson University and Hospitals found a way to make prostate biopsies easier and less invasive with the help of contrast-enhanced ultrasound.
This technique uses microscopic, shell-encased gas bubbles to visualize changes in blood flow, thus providing targeted guidance for needle placement during a biopsy. By comparison, standard ultrasound can help clinicians view the size of the prostate and the general area for needle insertion, but cannot tell the difference between benign and malignant tissues.
In order to evaluate the performance of this tool, the team of researchers conducted a phase III trial that included 311 men, who underwent a biopsy with either contrast-enhanced ultrasound or conventional techniques.
The newer modality detected 55 percent of clinically significant prostate cancers. That figure was 17 percent for the standard technique.
“Today, a physician may sample 12 to 18 tissue cores from the prostate in order to help diagnose a patient. But with contrast-enhanced, that number drops to six or even less,” said researcher Ethan Halpern, M.D. “So it’s less invasive, and a more effective guidance tool. We’ve found that with contrast-enhanced ultrasound, we are much more likely to detect cancers on the image, and in this case, the higher grades.”
The study is published in the Journal of Urology.
Nearly 242,000 men in the U.S. will be newly diagnosed with prostate cancer in 2012, as projected by the National Cancer Institute.
Content generated by Bankers Healthcare Group, the leader in providing financing options for medical professionals.